干扰素调节因子 4:达拉单抗治疗的多发性骨髓瘤患者血浆细胞的替代标记物

IF 2.2 4区 医学 Q3 HEMATOLOGY
Suwen Yang, Qianwen Hu, Xiaofen Wang, Sai Qiao, Chao Qi, Hong Jin, Yuhong Zhong
{"title":"干扰素调节因子 4:达拉单抗治疗的多发性骨髓瘤患者血浆细胞的替代标记物","authors":"Suwen Yang, Qianwen Hu, Xiaofen Wang, Sai Qiao, Chao Qi, Hong Jin, Yuhong Zhong","doi":"10.1111/ijlh.14366","DOIUrl":null,"url":null,"abstract":"IntroductionAnti‐CD38 therapeutic modalities (e.g., daratumumab) can impede classical CD38 and CD138 gating use for plasma cell (PC) detection in multiple myeloma (MM) patients with minimal residual disease (MRD). We assessed the applicability of CD229, CD269, and interferon regulatory factor (IRF‐4) for PC detection in MM MRD patients.MethodsBone marrow samples were collected from patients with MM. Through multiparameter flow cytometry, we evaluated the suitability of CD229, CD269, and IRF‐4 for distinguishing PCs from other hematopoietic cells and compared their expression pattern on normal PCs (nPCs) and aberrant PCs (aPCs). We also assessed IRF‐4 expression stability after sample storage under different conditions. A 10‐color MRD antibody panel was used to determine whether IRF‐4 is an alternative primary PC‐gating marker for MM MRD assessment.ResultsIRF‐4 was expressed specifically on all PCs; its mean fluorescence intensity (MFI) was highest on PCs among all hematopoietic cells. This MFI did not decrease even after sample storage at 4°C or 25°C for 72 h. In all 42 MRD assessment samples, except for samples (<jats:italic>n</jats:italic> = 10) with no PCs, the use of IRF‐4 enabled accurate nPC (<jats:italic>n</jats:italic> = 12), aPC (<jats:italic>n</jats:italic> = 13), and nPC + aPC (<jats:italic>n</jats:italic> = 7) identification. Even samples from daratumumab‐treated patients had high IRF‐4 MFI, with no difference between pre‐treatment and post‐treatment (<jats:italic>n</jats:italic> = 7; <jats:italic>p</jats:italic> = 0.610).ConclusionsIRF‐4 demonstrates high MFI on PCs, and it is not expressed on other leukocytes. In MM patients with MRD, daratumumab treatment does not affect IRF‐4 expression. IRF‐4 is a promising marker for PC identification in MRD assessment of MM patients undergoing anti‐CD38 therapy.","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma\",\"authors\":\"Suwen Yang, Qianwen Hu, Xiaofen Wang, Sai Qiao, Chao Qi, Hong Jin, Yuhong Zhong\",\"doi\":\"10.1111/ijlh.14366\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"IntroductionAnti‐CD38 therapeutic modalities (e.g., daratumumab) can impede classical CD38 and CD138 gating use for plasma cell (PC) detection in multiple myeloma (MM) patients with minimal residual disease (MRD). We assessed the applicability of CD229, CD269, and interferon regulatory factor (IRF‐4) for PC detection in MM MRD patients.MethodsBone marrow samples were collected from patients with MM. Through multiparameter flow cytometry, we evaluated the suitability of CD229, CD269, and IRF‐4 for distinguishing PCs from other hematopoietic cells and compared their expression pattern on normal PCs (nPCs) and aberrant PCs (aPCs). We also assessed IRF‐4 expression stability after sample storage under different conditions. A 10‐color MRD antibody panel was used to determine whether IRF‐4 is an alternative primary PC‐gating marker for MM MRD assessment.ResultsIRF‐4 was expressed specifically on all PCs; its mean fluorescence intensity (MFI) was highest on PCs among all hematopoietic cells. This MFI did not decrease even after sample storage at 4°C or 25°C for 72 h. In all 42 MRD assessment samples, except for samples (<jats:italic>n</jats:italic> = 10) with no PCs, the use of IRF‐4 enabled accurate nPC (<jats:italic>n</jats:italic> = 12), aPC (<jats:italic>n</jats:italic> = 13), and nPC + aPC (<jats:italic>n</jats:italic> = 7) identification. Even samples from daratumumab‐treated patients had high IRF‐4 MFI, with no difference between pre‐treatment and post‐treatment (<jats:italic>n</jats:italic> = 7; <jats:italic>p</jats:italic> = 0.610).ConclusionsIRF‐4 demonstrates high MFI on PCs, and it is not expressed on other leukocytes. In MM patients with MRD, daratumumab treatment does not affect IRF‐4 expression. IRF‐4 is a promising marker for PC identification in MRD assessment of MM patients undergoing anti‐CD38 therapy.\",\"PeriodicalId\":14120,\"journal\":{\"name\":\"International Journal of Laboratory Hematology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-09-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Laboratory Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ijlh.14366\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Laboratory Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ijlh.14366","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

引言抗 CD38 治疗方法(如达拉单抗)可能会阻碍对患有极小残留病(MRD)的多发性骨髓瘤(MM)患者进行经典的 CD38 和 CD138 门检测浆细胞(PC)。我们评估了CD229、CD269和干扰素调节因子(IRF-4)在MM MRD患者PC检测中的适用性。通过多参数流式细胞术,我们评估了 CD229、CD269 和 IRF-4 在区分 PC 与其他造血细胞方面的适用性,并比较了它们在正常 PC(nPC)和异常 PC(aPC)上的表达模式。我们还评估了不同条件下样本储存后 IRF-4 表达的稳定性。结果IRF-4在所有PC上都有特异性表达;在所有造血细胞中,PC上的平均荧光强度(MFI)最高。在所有 42 份 MRD 评估样本中,除了没有 PC 的样本(n = 10)外,IRF-4 都能准确鉴定 nPC(n = 12)、aPC(n = 13)和 nPC + aPC(n = 7)。结论IRF-4在PC上的MFI很高,在其他白细胞上没有表达。在有MRD的MM患者中,达拉土单抗治疗不会影响IRF-4的表达。在对接受抗CD38治疗的MM患者进行MRD评估时,IRF-4是一种很有希望的PC鉴定标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma
IntroductionAnti‐CD38 therapeutic modalities (e.g., daratumumab) can impede classical CD38 and CD138 gating use for plasma cell (PC) detection in multiple myeloma (MM) patients with minimal residual disease (MRD). We assessed the applicability of CD229, CD269, and interferon regulatory factor (IRF‐4) for PC detection in MM MRD patients.MethodsBone marrow samples were collected from patients with MM. Through multiparameter flow cytometry, we evaluated the suitability of CD229, CD269, and IRF‐4 for distinguishing PCs from other hematopoietic cells and compared their expression pattern on normal PCs (nPCs) and aberrant PCs (aPCs). We also assessed IRF‐4 expression stability after sample storage under different conditions. A 10‐color MRD antibody panel was used to determine whether IRF‐4 is an alternative primary PC‐gating marker for MM MRD assessment.ResultsIRF‐4 was expressed specifically on all PCs; its mean fluorescence intensity (MFI) was highest on PCs among all hematopoietic cells. This MFI did not decrease even after sample storage at 4°C or 25°C for 72 h. In all 42 MRD assessment samples, except for samples (n = 10) with no PCs, the use of IRF‐4 enabled accurate nPC (n = 12), aPC (n = 13), and nPC + aPC (n = 7) identification. Even samples from daratumumab‐treated patients had high IRF‐4 MFI, with no difference between pre‐treatment and post‐treatment (n = 7; p = 0.610).ConclusionsIRF‐4 demonstrates high MFI on PCs, and it is not expressed on other leukocytes. In MM patients with MRD, daratumumab treatment does not affect IRF‐4 expression. IRF‐4 is a promising marker for PC identification in MRD assessment of MM patients undergoing anti‐CD38 therapy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.50
自引率
6.70%
发文量
211
审稿时长
6-12 weeks
期刊介绍: The International Journal of Laboratory Hematology provides a forum for the communication of new developments, research topics and the practice of laboratory haematology. The journal publishes invited reviews, full length original articles, and correspondence. The International Journal of Laboratory Hematology is the official journal of the International Society for Laboratory Hematology, which addresses the following sub-disciplines: cellular analysis, flow cytometry, haemostasis and thrombosis, molecular diagnostics, haematology informatics, haemoglobinopathies, point of care testing, standards and guidelines. The journal was launched in 2006 as the successor to Clinical and Laboratory Hematology, which was first published in 1979. An active and positive editorial policy ensures that work of a high scientific standard is reported, in order to bridge the gap between practical and academic aspects of laboratory haematology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信